Physicians and drug company sales representatives

作     者：Davis, GF 

作者机构：Albany New York USA 

出 版 物：《AMERICAN JOURNAL OF MEDICINE》 (美国医学杂志)

年 卷 期：2000年第108卷第5期

页      面：432-432页

核心收录：

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

主　　题：制药工业 药物信息机构/经济学 药物信息机构/标准 教育 医学 继续/经济学 教育 医学 继续/标准 伦理学 医学 卫生服务使用研究 医师 美国 人类 

摘      要：The relationship, discussed in the August issue of the Journal(1,2), between physicians and drug companies is a growing ethical disgrace to the medical profession. Nearly all educational programs for physicians are now tainted by the perceived and often actual bias of speakers funded by drug companies. However, among physicians there is strong denial that we are influenced by pharmaceutical representatives. Ironically, this denial serves the drug companies well, bolstering a sense of impartiality in the face of aggressive marketing to gain physician acceptance and use of the companies□ drugs. Furthermore, this denial creates danger by making physicians much less critical than they should be of the information that they receive. Unless we search out the few journal articles that critique the drug company studies and data analyses, we do not realize the limitations of these studies until serious side effects start to appear and a drug?s use is curtailed.